X4 Pharmaceuticals (XFOR) Change in Accured Expenses (2017 - 2025)

X4 Pharmaceuticals has reported Change in Accured Expenses for 9 years, with the latest figure at $2.2 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses fell 35.12% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at -$2.0 million (down 128.25% YoY), and the FY2025 full-year result was -$2.0 million, down 128.25% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $2.2 million, down from $3.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.5 million in Q2 2023, with the low at -$7.8 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $520150.0 across 5 years, with a median of $640500.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 2540.3% — and 2025, when it sank 715.66%.
• X4 Pharmaceuticals' Change in Accured Expenses stood at -$1.2 million in 2021, then soared by 304.59% to $2.5 million in 2022, then plunged by 261.85% to -$4.0 million in 2023, then jumped by 182.54% to $3.3 million in 2024, then slumped by 35.12% to $2.2 million in 2025.
• The last three Change in Accured Expenses figures came in at $2.2 million (Q4 2025), $3.4 million (Q3 2025), and $227000.0 (Q2 2025), per Business Quant data.